UKCPA viewpoint: Tofacitinib raises risk of PE
There is an increased risk of pulmonary embolism in patients receiving tofacitinib 10mg twice daily says Mikin Patel, a gastroenterology lead pharmacist
Tofacitinib is a frst generation non-selective janus-kinase (JAK) inhibitor that is currently licensed for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA), with a recommended dose of 5mg twice daily.
In 2018 the European Medicines Agency (EMA) also approved tofacitinib as a treatment for ulcerative colitis (UC) with a recommended dose of 10mg twice daily for the frst eight weeks and thereafter 5mg twice daily.
Currently, the dosing of 10mg twice daily is only licensed in UC but an openlabel clinical trial (Study A3921133) has evaluated the safety of both tofacitinib 5mg and tofacitinib 10mg twice daily compared with a tumour necrosis factor inhibitor (TNFi) in RA patients.
The trial identifed that the overall incidence of pulmonary embolism (PE) was fve-fold higher in the tofacitinib 10mg twice daily arm of the study compared with the TNF inhibitor arm, and approximately three-fold higher than tofacitinib in other studies across the tofacitinib programme.
Based on this safety concern, patients receiving tofacitinib, irrespective of indication, should be monitored for the signs and symptoms of PE and be advised to seek medical attention immediately if they experience them.
The EMA Pharmacovigilance Risk Assessment Committee (PRAC) – the committee responsible for the evaluation of safety issues for human medicines – is recommending that the 10mg twice daily dose is not prescribed to patients who are at high risk of PE until the risk has been reviewed.
If a patient has known rheumatoid arthritis, psoriatic arthritis or ulcerative colitis, and is under the care of a consultant from secondary care, it is important to check whether they are taking tofacitinib.
These patients should be monitored for the signs and symptoms of pulmonary embolism, and be advised to seek medical attention if this is the case.
An in-depth review is currently being carried out by the Pharmacovigilance Risk Assessment Committee, which will subsequently make a set of recommendations. These recommendations will then be forwarded to the Committee for Medicinal Products for Human Use (CHMP), which will adopt an opinion.
The fnal stage in the process is the adoption by the European Commission of a legally binding decision.
For more information about the UKCPA visit their website.
This column is produced in association with the UKCPA. The views expressed are those of the author and are not necessarily those of either Pharmacy Magazine or the UKCPA.
Record my learning outcomes
Inspiring stories related to health, fitness and the pursuit of wellbeing
More like this
Applications open for foundation pharmacist training
CPPE has opened applications for the newest intake of pharmacists on its foundation pharmacist training pathway. Limited places are available.
1 Min Article
Managing hay fever: help meet your customers' needs
This module will improve your hay fever knowledge, helping you to understand its impact on sufferers and recommend the right products to ease symptoms
15 Min Module